Cantargia
Develops antibody treatments targeting IL1RAP for cancer and autoimmune/inflammatory diseases.
CANTA | ST
Overview
Corporate Details
- ISIN(s):
- SE0006371126 (+3 more)
- LEI:
- 549300GKWRT7RXI4VS85
- Country:
- Sweden
- Address:
- Scheelevägen 27, 223 63 Lund
- Website:
- https://cantargia.com/en/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Cantargia is a biotechnology company developing antibody-based treatments for life-threatening diseases, focusing on cancer and autoimmune/inflammatory conditions. The company's core technology targets the interleukin-1 receptor accessory protein (IL1RAP). Its lead clinical candidate, nadunolimab (CAN04), is an antibody in Phase II development for cancer therapy. Its second program, CAN10, an antibody for autoimmune and inflammatory diseases, was acquired by Otsuka Pharmaceutical, validating the potential of Cantargia's proprietary IL1RAP-targeting platform.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-02 07:30 |
Board/Management Information
Cantargia utser Dr Wolfram Dempke till Chief Medical Officer
|
Swedish | 102.8 KB | ||
| 2025-10-02 07:30 |
Board/Management Information
Cantargia appoints Dr. Wolfram Dempke as Chief Medical Officer
|
English | 103.2 KB | ||
| 2025-09-11 07:30 |
M&A Activity
Cantargia closes the acquisition of CAN10 by Otsuka
|
English | 104.2 KB | ||
| 2025-09-11 07:30 |
M&A Activity
Cantargia slutför Otsukas förvärv av CAN10
|
Swedish | 103.9 KB | ||
| 2025-08-21 07:00 |
Interim Report
|
Swedish | 3.5 MB | ||
| 2025-08-21 07:00 |
Interim Report
|
English | 3.5 MB | ||
| 2025-08-18 18:25 |
Board/Management Information
Cantargia utnämner Dr Hilde Steineger till verkställande direktör
|
Swedish | 107.1 KB | ||
| 2025-08-18 18:25 |
Board/Management Information
Cantargia appoints Dr Hilde Steineger as Chief Executive Officer
|
English | 107.8 KB | ||
| 2025-07-17 21:30 |
Regulatory News Service
Cantargia announces preliminary topline efficacy results from the phase 2 TRIFO…
|
English | 117.3 KB | ||
| 2025-07-17 21:30 |
Earnings Release
Cantargia meddelar preliminära topline-effektresultat från fas 2-studien TRIFOU…
|
Swedish | 118.2 KB | ||
| 2025-07-15 08:45 |
M&A Activity
Cantargia tillkännager försäljningen av IL1RAP immunologiprogrammet CAN10 till …
|
Swedish | 111.6 KB | ||
| 2025-07-15 08:45 |
M&A Activity
Cantargia announces the acquisition of its CAN10 IL1RAP immunology program by O…
|
English | 111.5 KB | ||
| 2025-07-08 10:17 |
Major Shareholding Notification
|
Swedish | 9.5 KB | ||
| 2025-06-17 19:45 |
Capital/Financing Update
Cantargia tecknar avtal om lånefacilitet om 50 miljoner kronor, som förlänger b…
|
Swedish | 107.1 KB | ||
| 2025-06-17 19:45 |
Capital/Financing Update
Cantargia signs SEK 50 million financing facility agreement, extending cash run…
|
English | 107.4 KB |
Automate Your Workflow. Get a real-time feed of all Cantargia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cantargia
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cantargia via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-19 | Nedjad Losic | Other | Buy | 21,375 | 33,131.25 SEK |
| 2025-01-02 | Antonius Franciscus Berkien | Other | Other | 21,621 | 39,998.85 SEK |
| 2024-12-20 | Göran Forsberg | Other | Other | 152,206 | 281,581.10 SEK |
| 2024-12-20 | Nedjad Losic | Other | Other | 12,875 | 23,818.75 SEK |
| 2024-12-09 | Antonius Franciscus Berkien | Other | Buy | 3,741 | 6,733.80 SEK |
| 2023-01-19 | Nedjad Losic | Other | Buy | 3,918 | 29,110.74 SEK |
| 2023-01-17 | Göran Forsberg | Other | Buy | 17,000 | 140,250.00 SEK |
| 2023-01-17 | Bengt Jöndell | Other | Buy | 6,500 | 54,665.00 SEK |
| 2022-07-28 | Göran Forsberg | Other | Other | 91,765 | 344,118.75 SEK |
| 2022-07-28 | Thoas Fioretos | Other | Other | 78,400 | 294,000.00 SEK |
